StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for CLNN yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $7.21 | $6.79 | -5.83% | 0.1M |
| 05-19 | $6.77 | $6.38 | -5.76% | 0.2M |
| 05-20 | $6.36 | $6.90 | +8.49% | 0.1M |
| 05-21 | $6.84 | $6.81 | -0.44% | 0.1M |
| 05-22 | $6.85 | $6.70 | -2.19% | 0.1M |
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2023 2023-09-30 | Q2 2023 2023-06-30 | Q1 2023 2023-03-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $484.00K | $376.00K | $107.00K | $473.00K |
Operating Income | $-30.61M | $-21.07M | $-10.73M | $-48.41M |
Net Income | $-39.33M | $-25.14M | $-11.77M | $-29.92M |
EPS (Diluted) | $-8.11 | $-9.11 | $-0.15 | $-0.46 |
Total Assets | $60.43M | $67.84M | $39.89M | $44.49M |
Total Liabilities | $39.03M | $46.31M | $41.52M | $41.26M |
Cash & Equivalents | $42.11M | $49.24M | $18.44M | $18.33M |
Free Cash Flow OCF − CapEx | $-23.29M | $-16.48M | $-9.50M | $-44.19M |
Shares Outstanding | 128.41M | 128.40M | 77.99M | 74.76M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.